Design-based theory for Lasso adjustment in randomized block experiments and rerandomized experiments
随机区组与再随机化实验中 Lasso 调整的设计型理论AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要研究随机实验中平均处理效应的回归调整、效率和设计型推断。
随机区组与再随机化实验中 Lasso 调整的设计型理论AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Blocking, a special case of rerandomization, is routinely implemented in the design stage of randomized experiments to balance the baseline covariates. This study proposes a regression adjustment method based on the least absolute shrinkage and selection operator (Lasso) to efficiently estimate the average treatment effect in randomized block experiments with high-dimensional covariates. We derive the asymptotic properties of the proposed estimator and outline the conditions under which this estimator is more efficient than the unadjusted one. We provide a conservative variance estimator to facilitate valid inferences. Our framework allows one treated or control unit in some blocks and heterogeneous propensity scores across blocks, thus including paired experiments and finely stratified experiments as special cases. We further accommodate rerandomized experiments and a combination of blocking and rerandomization. Moreover, our analysis allows both the number of blocks and block sizes to tend to infinity, as well as heterogeneous treatment effects across blocks without assuming a true outcome data-generating model. Simulation studies and two real-data analyses demonstrate the advantages of the proposed method.
连接局部与总体因果效应:近端工具变量方法
Instrumental variable (IV) methods address treatment endogeneity, but with non-compliance and heterogeneous treatment effects a binary instrument generally identifies the local average treatment effect (LATE) among compliers rather than the population average treatment effect (ATE). When treatment effects and compliance probabilities are heterogeneous and dependent through latent factors, the ATE need not be identified by IV variation alone. We develop a proximal…
基于方差的治疗效应异质性检验
This paper proposes a robust nonparametric hypothesis test for the existence of heterogeneous treatment effects. We focus on the variance of the Conditional Average Treatment Effect (CATE) as a natural omnibus parameter, where a non-zero variance implies the presence of relevant heterogeneity. Standard inference for this parameter faces a fundamental theoretical challenge. On one hand, evaluating variance components on the same sample leads to null degeneracy, where the…
以双重校准借用观察数据提升随机试验 CATE 估计精度
Understanding how treatment effects vary across patient characteristics is essential for personalized medicine, yet randomized controlled trials (RCTs) are often underpowered to detect heterogeneous treatment effects (HTEs). We propose a framework that improves the efficiency of conditional average treatment effect (CATE) estimation in RCTs by leveraging large observational studies (OS) while preserving RCT unbiasedness. Framing CATE estimation as a supervised learning…
主分层下异质性处理效应的双重交叉拟合去偏机器学习
Principal stratification provides a foundational framework for causal inference with intermediate outcomes by defining causal effects within subpopulations, yet existing work has largely focused on average effects across strata rather than treatment effect heterogeneity within strata. Such within-stratum heterogeneity informs individualized treatment decisions but the associated methods are sparse. We address this gap by studying the identification and estimation of the…
AMP 艾滋病预防试验中地区特异性生存效应的定向数据融合
The Antibody Mediated Prevention (AMP) trials opened a new scientific frontier by showing that passively administered monoclonal broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition. Conducted across multiple geographic regions, including the United States, Brazil, Peru, Switzerland, and sub-Saharan Africa, the AMP trials revealed substantial regional heterogeneity in treatment efficacy. These differences, together with privacy and regulatory limits on…
组间不平衡下的风险异质性稳健推断
Population-level heterogeneity is ubiquitous in biomedical data, where differences across demographic or clinical subgroups can substantially alter risk patterns. For example, in intensive care unit (ICU) studies, the mortality risk associated with specific admission diagnoses can vary across ethnic groups. Existing approaches for detecting risk heterogeneity are often sensitive to baseline model misspecification and regularization bias, both of which commonly arise in…